Geistlich Pharma has entered an exclusive national distribution collaboration agreement with StimLabs in the US, focusing on the commercialisation of the former’s Advanced Wound Matrix, Derma-Gide.
Derma-Gide is a 510k cleared, porcine-derived solution for both acute and chronic wounds. It is claimed to be processed using proprietary technologies and is specifically indicated for wound management.
The product’s “unique” design characteristics are claimed to be tailored to support healthcare providers with ease of use and handling.
Related: Acorai closes $4.5M investment from the European Innovation Council Fund
Geistlich Pharma has “expertise” in transforming source tissues into an advanced design with precise characteristics that aid in wound healing.
Geistlich CEO Diego Gabathuler said: “Geistlich is very pleased to have StimLabs as an exclusive distribution partner of Derma-Gide in the US and is looking forward to supporting our joint success moving forward.
“With Derma-Gide, now listed as covered in the recently published US Centers for Medicare & Medicaid Services’ (CMS) local coverage determination (LCD) for diabetic foot ulcers (DFUs), StimLabs will leverage their national channel to support clinicians in the adoption and utilisation of this highly differentiated technology. And we are excited to offer our Advanced Wound Matrix to patients suffering from difficult-to-heal wounds.”
Derma-Gide features a bi-layered design that closely resembles the structural organisation of human skin, promoting re-epithelialisation and cell ingrowth.
The integrated structure of the product is a result of the refinement process, with both layers mechanically linked to create a durable and user-friendly solution.
